Awareness of detoxification, nowadays known as biotransformation, has become an integral part of our daily lives. It is a modern buzz word that is used to promote anything from health food to enhancement of performance in sports. Another lesser known application for detoxification is as a therapy for alleviating symptoms of inborn errors of metabolism. Detoxification is the process where endogenous and xenobiotic metabolites are transformed to less harmful products, in the liver and kidneys, in two phases. Phase 1 detoxification includes oxidation, hydroxylation, dehydrogenation metabolic reduction and hydrolysis. Phase 2 detoxification uses conjugation reactions to increase hydrophillicty of metabolites for excretion in bile and urine. Glycine N-acyltransferse (GLYAT; EC 2.3.1.13) is one of the amino acid conjugation enzymes. There are two variants of human GLYAT. I focused on the full-length mRNA human GLYAT isoform a, with a long term view of using it as a viable therapeutic enzyme for enhanced detoxification of harmful metabolites. I investigated if it is possible to clone and express a biologically active GLYAT. To achieve this goal I used three expression systems: traditional bacterial expression using the pET system; second generation cold shock bacterial expression using the pCOLDTF expression vector to improve solubility of the recombinant protein; and baculovirus expression in insect cells since therein some form of post translation glycosylation of the recombinant protein can occur which might improve solubility and ensure biological activity. The recombinant GLYAT expressed well in all three expression systems but was aggregated and no enzyme activity could be detected. A denature and renature system was also used to collect aggregated recombinant GLYAT and used to try to refold the recombinant protein in appropriate refolding buffers to improve solubility and obtain biological activity. The solubility of the recombinant GLYAT was improved but it remained biologically inactive. / Thesis (MSc (Biochemistry))--North-West University, Potchefstroom Campus, 2013.

Made available in DSpace on 2016-06-02T19:56:29Z (GMT). No. of bitstreams: 1 1471.pdf: 1734309 bytes, checksum: e1a25902d99a75515b696dcd901f26a8 (MD5) Previous issue date: 2007-03-28 / Universidade Federal de Sao Carlos / In animal cell cultures there are two kinds of cell death: apoptosis (programmed cell death) and necrosis (cell death due to external sources). The inovative method of cell death identification that have attracted interest is the use of fluorescence microscopy and fluorescent dye (to bind DNA and RNA). Image analysis techniques has become a useful tool in cell death quantification, once they are non destructive for the culture and have easy application with using adjusted softwares. Based in these new technological trends, the present work considers the development of a methodology for quantification of apoptotic and necrotic cell death in cultures of insect cells Drosophila melanogaster (S2). This methodology involved the development of a experimental procedure using new dyes (YO-PRO-1 and Propidium Iodide), that have presented advantages over the others because they are non destructive to the culture an are able to clearly discriminate between apoptotic and necrotic cell death. The use of this dyes was compared with the method of exclusion of Trypan blue and fluorescent dyes Acridine Orange and Ethidium Bromide. Besides being less toxic to cells S2, YO-PRO-1 and Propidium Iodide showed more sensitivity in the identification of death and in the calculation of cell viability. It also envolved the development of an algorithm based on image analysis techniques for quantification of the two kinds of cell death, less subjective than the manual methods currently used. The algorithm showed to be efficient, fast an of easy application with a error around 2% when compared to manual methodology. The calculated cell concentration by the algorithm was very close to experimental. / Em cultivos de células animais existem dois tipos de morte celular: apoptose (morte celular programada) e necrose (morte devido a lesões causadas por fontes externas). O método inovador de identificação dessas mortes de células que tem atraído muito interesse é o uso de microscopia de fluorescência e corantes celulares fluorescentes capazes de tingir moléculas de DNA e RNA. Técnicas de análise de imagem têm se tornado uma ferramenta útil nessa quantificação de morte celular, uma vez que é não destrutiva para a cultura e de fácil aplicação com o uso de softwares adequados. Baseado nessas novas tendências tecnológicas, o presente trabalho teve como meta o desenvolvimento de uma metodologia para quantificação de morte apoptótica e necrótica no cultivo de células de inseto Drosophila melanogaster (S2). Essa metodologia envolveu o desenvolvimento de um procedimento experimental utilizando corantes novos no mercado: o YO-PRO-1 e o Iodeto de Propídio, que têm apresentado vantagens sobre os outros corantes por não serem destrutivos para a cultura e discriminarem claramente a morte apoptótica da necrótica. A metodologia que faz uso destes corantes foi comparada com o método de exclusão por Azul de Tripan e com os corantes fluorescentes Laranja de Acridina e Brometo de Etídio. Além de serem menos tóxicos as células, o YO-PRO-1 e o Iodeto de Propído mostraram mais sensibilidade na identificação da morte e posterior cálculo da viabilidade celular. A metodologia também envolveu o desenvolvimento de um algoritmo baseado em técnicas de análise de imagens para quantificação dos dois tipos de morte celular, menos subjetiva que os métodos manuais atualmente utilizados. O algoritmo se mostrou eficiente, rápido e de fácil aplicação, gerando um erro de 2% quando comparado com a metodologia manual. Também realizou-se o cálculo da concentração celular por método computacional, ficando os valores bem próximos dos experimentais.

O cDNA da glicoproteína do vírus da raiva (GPV) foi clonado em vetores plasmidiais (indutíveis) contendo ou não o cDNA do sinal de secreção BiP e da resistência ao antibiótico higromicina B. Esses vetores foram transfectados em células S2 e foram obtidas populações e subpopulações. A população S2MTGPV-H apresentou níveis 5x maiores na expressão da GPV em análise por FACS (~ 50% das células) e por ELISA (~ 0,65 µg/107 células). A seleção de subpopulações permitiu um aumento de aproximadamente 10x na expressão da GPV, especialmente na população S2MTGPV*-H. O tratamento com NaBu resultou em uma redução de aproximadamente 20% no crescimento celular e um aumento de 50% na GPV expressa pela população S2MTGPV*-H (~ 8,3 µg/107 células). O meio de cultura SF900 II permitiu um maior crescimento das células S2MTGPV*-H e uma maior síntese de GPV comparado com outros meios de cultura. Nossos dados mostram que a expressão da GPV pôde ser otimizada através da construção de vetores de expressão/seleção, subpopulações, da exposição da cromatina e do meio de cultura utilizado. / The cDNA encoding the entire rabies virus glycoprotein (RVGP) gene was cloned in plasmids (inductive) with or without a cDNA coding for the secretion signal and coding for the selection hygromicin antibiotic. These vectors were transfected into S2 cells and we had obtain cells populations and subpopulations S2MTRVGP-H cell population were shown to express 5 times higher of RVGP as evaluated by FACS (~ 50 %) and ELISA (~ 0.65 mg/107 cells at day 7). Sub-population selection allowed a higher RVGP expression, especially for the S2MTRVGP*-H. NaBu treatment leading to lower cell growth and higher RVGP expression allowed an even higher RVGP synthesis by S2MTRVGP*-H (~ 8.3 mg/107 cells at day 7 after induction). SF900II medium leading to a higher S2MTRVGP*-H cell growth allowed a higher final RVGP synthesis in this cell culture. The data show that RVGP synthesis may be optimized by the expression/selection vectors design, cell sub-populations selection, chromatine exposure and culture medium employed.

O interesse em células de inseto para a produção de proteínas complexas se deve a sua maior facilidade de cultivo e ao padrão equivalente de glicosilação quando comparado aos sistemas com células de mamíferos. O objetivo deste trabalho foi identificar fatores que limitam ou inibem a produção da glicoproteína do vírus rábico (GPV) expressa na membrana citoplasmática de células de Drosophila melanogaster transfectadas, quando cultivadas em biorreator de bancada agitado e bubble-free, operado em modo descontínuo. Avaliaram-se as influências de oxigênio dissolvido (5 < pO2 <80%), da glicose (1 < GLC0 < 15g/L) e da glutamina (0.6 < GLN0 < 7g/L). Essas variáveis afetaram de forma diferenciada o crescimento celular (produção de células e velocidades específicas-µX), o metabolismo celular (fatores de conversão - YX/GLC, YX/GLN, YLAC/GLC, YALA/GLC, YNH4/GLN, YALA/GLN), assim como a expressão da proteína recombinante (concentração, teor celular e produtividade). O aumento do pO2 reduziu em 9 vezes o crescimento celular mas aumentou o teor celular de GPV em 1,4 vezes. Baixos valores de GLC0 e GLN0, claramente, limitaram o crescimento, de modo que incrementos na concentração desses substratos, até valores intermediários, aumentaram µX,MAX em 3 vezes e 2,5 vezes, respectivamente, e a produção de células em 11 vezes e 3 vezes, respectivamente. O teor celular de GPV máximo não foi afetado pela GLC, mas aumentou em 100% para valores de GLN0 igual ou superiores a 3,5 g/L. As concentrações de lactato produzidas foram consideradas baixas (inferiores a 0,8 g/L) para exercer qualquer efeito de inibição sobre o crescimento ou a expressão da proteína. Por sua vez, as concentrações de amônio parecem inibir tanto a produção de GPV (NH4+~50mg/L) quanto o crescimento celular (NH4+~80mg/L). A condição de cultivo com de 30% de pO2, 10 g/L de GLC0 e 3,5 g/L de GLN0 resultou nos maiores valores de produtividade (9,1 µg/L.h) e de concentração de GPV (1,2 mg/L). O metabolismo de GLC e GLN apresentou grande interdependência, com alterações em GLC0 afetando o metabolismo de GLN e vice-versa. Assim, em condições de excesso de GLC0, as células apresentaram um metabolismo mais ineficiente com reduções nos fatores YX/GLC (2,3 vezes) e YX/GLN (4,6 vezes) e maior geração de subprodutos, caracterizada por incrementos nos valores de YALA/GLC (51%), YLAC/GLC (11%) e YNH4/GLN (15%). O metabolismo da GLN apresentou resposta característica de substrato em excesso para toda a faixa de valores ensaiada, com redução de 25 vezes no valor de YX/GLN e inesperadamente também uma redução na geração de subprodutos de 7 vezes para YNH4/GLN e 12 vezes para YALA/GLN. O efeito sobre o metabolismo da GLC foi mais acentuado para valores mais elevados de GLN0, com redução de 3,6 vezes para YX/GLC e incrementos de 70% para YALA/GLC e para YLAC/GLC. Os resultados sugerem ainda que a célula utiliza duas vias para metabolizar a glutamina: glutaminólise, em condição de limitação em GLC; ou glutamato sintase - NADH-GOGAT, em condição de excesso em GLC. A célula demonstrou também capacidade de sintetizar GLN, a partir de amônio ou outros aminoácidos, quando atingiu concentrações abaixo de 50 mg/L. / The interest in using insect cells to produce complex proteins is due to its ease of cultivation and its glycosylation pattern equivalent to that of mammalian cells systems. The objective of this work was to identify the limiting or inhibiting factors for the production of a rabies virus glycoprotein (RVGP), expressed in the cytoplasmatic membrane of a transfected Drosophila melanogaster S2 cells, when cultivated in a bench stirred bubble-free bioreactor, in batch mode. The influence of dissolved oxygen (5 < pO2 < 80%), of initial glucose concentration (1 < GLC0 < 15 g/L) and of initial glutamine concentration (0.6 < GLN0 < 7 g/L) was evaluated. These variables affected in a different way cell growth (cell production and specific growth rate - µX), cell metabolism (yield factors - YX/GLC, YX/GLN, YLAC/GLC, YALA/GLC, YNH4/GLN and YALA/GLN), as well as the recombinant protein expression (RVGP concentration, RVGP cell content and RVGP productivity). pO2 increase reduced 9 times cell growth, but increased 1.4 times RVGP cell content. Low initial glucose and glutamine concentrations clearly limited the cell growth, in such a way that raising these substrates concentrations up to intermediate values, increased µX,MAX 3 times and 2.5 times, respectively, and increased cell production 11 times and 3 times, respectively. The maximum RVGP cell content was not affected by GLC0, but improved 100% when GLN0 was 3.5 g/L or higher. The concentrations of produced lactate were considered low (below 0.8 g/L) to cause any inhibition effect on growth or protein expression. On the other hand, ammonium concentrations seem to inhibit RVGP production (NH4+~50 mg/L), as well as cell growth (NH4+~80 mg/L). Maximum productivity values (9.1 µg/L.h) and RVGP concentration (1.2 mg/L) were attained for 30% pO2, 10 g/L of GLC0 and 3.5 g/L of GLN0 run. The metabolism of GLC and GLN showed a great interdependence, with GLC0 changes affecting the GLN metabolism, and viceversa. Thus, in glucose excess condition, cell metabolism was less efficient. This implied in reduction of yield factors - YX/GLC (2.3 times) e YX/GLN (4.6 times) - and in higher by-products generation, characterized by augmentation in YALA/GLC (51%), YLAC/GLC (11%) and YNH4/GLN (15%). The glutamine metabolism showed a substrate excess response pattern to the whole range of concentration studied, with reduction of YX/GLN (25 times) and, unexpectedly, a reduction of by-products liberation - YNH4/GLN (7 times) and YALA/GLN (12 times). The effect on glucose metabolism was more intense when the glutamine concentration was higher, showing a 3.6 times diminution YX/GLC and a 70% augmentation for YALA/GLC and YLAC/GLC. The results suggest that cells metabolize glutamine through two different pathways glutaminolysis, under glucose limitation, or glutamate synthase - NADH-GOGAT, under glucose excess. The cell, proved also to be able to synthesize glutamine from ammonium or other amino acids, when it reached concentrations below 50 mg/L.

The aim of this study was to better understand the role of conditioned medium (CM) in Spodoptera frugiperda Sf9 insect cell proliferation and recombinant protein production using the baculovirus expression system. CM was found to stimulate cell proliferation. Addition of CM and 10 kDa CM filtrate to an Sf9 culture decreased the lagphase and the maximum cell density was reached earlier than for cultures in fresh medium. The positive effect of 10 kDa CM filtrate showed that CM contains at least one small growth promoting factor. The effect was not eliminated by trypsin treatment. Addition of CM or 10 kDa CM filtrate to Sf9 cultures was found to have a negative effect on the recombinant protein production. The effect was thought to be indirect and most probably via the impact of CM on cell physiology. CM was also found to contain proteinase activity. The proteinase was identified as Sf9 cathepsin L. A proform with a molecular mass about 49 kDa and two active forms at about 39 and 22 kDa were found. The role of cathepsin L in Sf9 cultures is not yet clear. However, the knowledge of the presence of this proteinase in CM can be of great value for improving product quality and yield. Further, CM was found to have other properties as well: a concentrated fraction of CM exhibited strong antibacterial activity towards Bacillus megaterium and a weaker activity towards Escherichia coli. B. megaterium lysed rapidly after incubation in the CM fraction. Repeated subculturing of Sf9 cells provoked a switch in growth kinetics. After 30-45 passages the cells started to proliferate earlier after inoculation and addition of CM had no longer a growth stimulating effect. However, CM still stimulated growth of a culture with low passage (LP) number (up to 45 passages). High passage cells (HP cells, over 100 passages) displayed a shorter lagphase than LP cells and the culture reached the maximum cell density 24-48 h earlier. Cell cycle analysis showed that the Sf9 cells were transiently synchronised in the G2/M phase 10 h after inoculation, before proliferation was initiated. This synchronisation was more pronounced for HP cells than for LP cells, which correlated to a higher recombinant protein production in baculovirus infected HP cells than in LP cells. Synchronisation of cells in G2/M by yeastolate-limitation before infection with baculoviruses suggested that the degree of synchronisation is connected to the cell density dependent decrease in recombinant protein production of Sf9 cultures. / QC 20101222

Tesis por compendio / [EN] Carbamoyl phosphate synthetase 1 (CPS1), a 1462-residue mitochondrial enzyme, catalyzes the entry of ammonia into the urea cycle, which converts ammonia, the neurotoxic waste product of protein catabolism, into barely toxic urea. The urea cycle inborn error and rare disease CPS1 deficiency (CPS1D) is inherited with mendelian autosomal recessive inheritance, being due to CPS1 gene mutations (>200 mutations reported), and causing life-threatening hyperammonemia. We have produced recombinantly human CPS1 (hCPS1) in a baculovirus/insect cell expression system, isolating the enzyme in active and highly purified form, in massive amounts. This has allowed enzyme crystallization for structural studies by X-ray diffraction (an off-shoot of the present studies). This hCPS1 production system allows site-directed mutagenesis and enzyme characterization as catalyst (activity, kinetics) and as protein (stability, aggregation state, domain composition). We have revealed previously unexplored traits of hCPS1 such as its domain composition, the ability of glycerol to replace the natural and essential CPS1 activator N-acetyl-L-glutamate (NAG), and the hCPS1 protection (chemical chaperoning) by NAG and by its pharmacological analog N-carbamyl-L-glutamate (NCG). We have exploited this system to explore the effects on the activity, kinetic parameters and stability/folding of the enzyme, and to test the disease-causing nature, of mutations identified in patients with CPS1 deficiency (CPS1D). These results, supplemented with those obtained with other non-clinical mutations, have provided novel information on the functions of three non-catalytic domains of CPS1. We have introduced three CPS1D-associated mutations and one trivial polymorphism in the glutaminase-like domain of CPS1, supporting a stabilizing and an activity-enhancing function of this non-catalytic domain. Two mutations introduced into the bicarbonate phosphorylation domain have shed light on bicarbonate binding and have directly confirmed the importance of this domain for NAG binding to the distant (in the sequence) C-terminal CPS1 domain. The introduction of 18 CPS1D-associated missense mutations mapping in a clinically highly eloquent central non-catalytic domain have proven the disease-causing nature of most of these mutations while showing that in most of the cases they trigger enzyme misfolding and/or destabilization. These results, by proving an important role of this domain in the structural integration of the multidomain CPS1 protein, have led us to call this domain the Integrating Domain. Finally, we have examined the effects of eight CPS1D-associated mutations, of one trivial polymorphism and of five non-clinical mutations, all of them mapping in the C-terminal domain of the enzyme where NAG binds, whereas we have re-analyzed prior results with another four clinical and five non-clinical mutations affecting this domain. We have largely confirmed the pathogenic nature of the clinical mutations, predominantly because of decreased activity, in many cases due to hampered NAG binding. A few mutations had substantial negative effects on CPS1 stability/folding. Our analysis reveals that NAG activation begins with a movement of the final part of the ß4-¿4 loop of the NAG site. Transmission of the activating signal to the phosphorylation domains involves helix ¿4 from this domain and is possibly transmitted by the mutually homologous loops 1313-1332 and 778-787 (figures are residue numbers) belonging, respectively, to the carbamate and bicarbonate phosphorylation domains. These two homologous loops are called from here on Signal Transmission Loops. / [ES] La carbamil fosfato sintetasa 1 (CPS1), una enzima mitocondrial, cataliza la entrada del amonio en el ciclo de la urea, que convierte esta neurotoxina derivada del catabolismo de las proteínas en urea, mucho menos tóxica. El déficit de CPS1 (CPS1D) es un error innato del ciclo de la urea, una enfermedad rara autosómica recesiva, que se debe a mutaciones en el gen CPS1 (>200 mutaciones descritas) y que cursa con hiperamonemia. Hemos producido CPS1 humana recombinante (hCPS1) en un sistema de expresión de células de insecto y baculovirus, y la hemos aislado en forma activa, muy pura y en cantidad elevada. Este sistema de producción de hCPS1 permite la realización de mutagénesis dirigida y la caracterización de la enzima como catalizador (actividad, cinética) y como proteína (estabilidad, estado de agregación y composición de dominios). Hemos revelado características de la hCPS1 antes no exploradas como es la composición de dominios, la capacidad que tiene el glicerol para reemplazar al activador natural y esencial de la CPS1, N-acetil-L-glutamato (NAG), y la protección de la hCPS1 por NAG y por su análogo farmacológico N-carbamil-L-glutamato (NCG) (chaperonas químicas). Hemos utilizado este sistema para explorar los efectos en actividad, parámetros cinéticos y estabilidad/plegamiento de la enzima, y para comprobar la naturaleza patogénica de mutaciones identificadas en pacientes con CPS1D. Estos resultados, junto con los obtenidos con otras mutaciones no clínicas, han aportado información novedosa sobre tres de los dominios no catalíticos de CPS1. Las observaciones realizadas tras introducir en el dominio de tipo glutaminasa de la enzima tres mutaciones asociadas a CPS1D y un polimorfismo trivial, apoyan la contribución de este dominio no catalítico a la estabilidad y a aumentar la actividad de la enzima. Dos mutaciones introducidas en el dominio de fosforilación de bicarbonato han arrojado luz sobre el modo de unión del bicarbonato (un sustrato). Los resultados de estas mutaciones también han confirmado la contribución de este dominio para la unión de NAG, cuyo sitio de unión se encuentra en el dominio C-terminal de CPS1, bastante alejado (en la secuencia) del dominio de fosforilación de bicarbonato. Además, hemos introducido 18 mutaciones de cambio de sentido asociadas a CPS1D, las cuales están localizadas en un dominio no catalítico, central y de elevada elocuencia clínica. Estos resultados han demostrado la naturaleza patogénica de estas mutaciones, ya que en la mayoría de los casos estas mutaciones producen un mal plegamiento o/y desestabilización de la enzima. Debido a que estos resultados han puesto de manifiesto el importante papel de este dominio en la integración estructural de la proteína multidominio CPS1, lo hemos llamado Dominio Integrador. Finalmente, hemos examinado los efectos de 8 mutaciones asociadas a CPS1D, de un polimorfismo trivial y de 5 mutaciones no clínicas, todas localizadas en el dominio C-terminal de la enzima, donde se une NAG. Además, hemos reanalizado resultados anteriores con otras 4 mutaciones clínicas y 5 no clínicas afectando a este dominio. Hemos confirmado el carácter patogénico de las mutaciones clínicas, las cuales predominantemente causan una disminución en la actividad enzimática, en muchos casos debida a que la unión de NAG se encuentra obstaculizada. Unas pocas mutaciones mostraron efectos negativos en la estabilidad/plegamiento de CPS1. Nuestros análisis revelan que la activación por el NAG empieza con un movimiento de la parte final del bucle ß4-¿4 del sitio de NAG. La transmisión de la señal activadora a los dominios de fosforilación implica a la hélice ¿4 de este dominio y posiblemente se transmite a través de los bucles homólogos 1313-1332 y 778-787 (numeración de residuos) pertenecientes, respectivamente, a los dominios de fosforilación de carbamato y bicarbonato. Por ello, hemos llamado a ambos bucles Bucles de / [CA] La carbamil fosfat sintetasa 1 (CPS1), un enzim mitocondrial, catalitza l'entrada d'amoni en el cicle de la urea, que convertix l'amoni, producte neurotòxic del catabolisme de les proteïnes, en urea, una molècula molt poc tòxica. El dèficit de CPS1 (CPS1D) és un error innat del cicle de la urea, una malaltia rara autosòmica recessiva, que es deu a mutacions en el gen CPS1 (>200 mutacions descrites) i que cursa amb hiperamonièmia. Hem produït CPS1 humana recombinant (hCPS1) en un sistema d'expressió de cèl·lules d'insecte i baculovirus, i l'hem aïllada en forma activa, molt pura i en gran quantitat. Això ha permés la cristal·lització de l'enzim per a estudis estructurals amb difracció de raios-X (treball no inclòs en esta tesi Aquest sistema de producció de hCPS1 permet la realització de mutagènesi dirigida i la caracterització de l'enzim com a catalitzador (activitat, cinètica) i com a proteïna (estabilitat, estat d'agregació i composició de dominis). Hem revelat característiques de la hCPS1 no explorades abans com és la composició de dominis, la capacitat que té el glicerol per a reemplaçar l'activador natural i essencial de CPS1, N-acetil-L-glutamat (NAG), i la protecció de la hCPS1 per NAG i pel seu anàleg farmacològic N-carbamil-L-glutamat (NCG) (xaperones químiques) . Hem utilitzat aquest sistema per a explorar els efectes en l'activitat, els paràmetres cinètics i l'estabilitat/plegament de l'enzim, i per a comprovar la naturalesa patogènica de mutacions identificades en pacients amb CPS1D. Aquestos resultats, junt amb els obtinguts amb altres mutacions no clíniques, han aportat informació nova sobre tres dels dominis no catalítics de la CPS1. Les observacions, després d'introduir tres mutacions associades a CPS1D i un polimorfisme trivial en el domini tipus glutaminasa de CPS1, recolzen la contribució d'aquest domini no catalític a l'estabilitat i a l'optimització de l'activitat enzimàtica. Dues mutacions introduïdes en el domini de fosforilació de bicarbonat han esclarit el mode d'unió de bicarbonat. Els resultats d'aquestes mutacions també han confirmat la contribució d'aquest domini per a la unió de NAG, el lloc d'unió de la qual es troba en el domini C-terminal de CPS1, prou allunyat (en la seqüència) del domini de fosforilació de bicarbonat. A més, hem introduït 18 mutacions de canvi de sentit associades a CPS1D, les quals estan localitzades en un domini no catalític, central i d'elevada eloqüència clínica. Aquestos resultats han demostrat la naturalesa patogènica d'aquestes mutacions, ja que, en la majoria dels casos produïxen un mal plegament o/i desestabilització de l'enzim. Pel fet que aquestos resultats han posat de manifest l'important paper d'aquest domini en la integració estructural de la proteïna multidomini CPS1, l'hem anomenat Domini Integrador. Finalment, hem examinat els efectes de huit mutacions associades a CPS1D, un polimorfisme trivial i cinc mutacions no clíniques, totes elles localitzades en el domini C-terminal de l'enzim, on s'unix NAG. A més, hem reanalitzat resultats anteriors amb altres quatre mutacions clíniques i cinc no clíniques que afecten aquest domini. Hem confirmat el caràcter patogènic de les mutacions clíniques, les quals predominantment causen una disminució en l'activitat enzimàtica, en molts casos pel fet que la unió de NAG es troba obstaculitzada. Unes poques mutacions van mostrar efectes negatius substancials en l'estabilitat/plegament de CPS1. Les nostres anàlisis revelen que l'activació de NAG comença amb un moviment de la part final del bucle ß4-¿4 del lloc de NAG. La transmissió del senyal activadora als dominis de fosforilació involucra l'hèlix ¿4 d'aquest domini i es transmet, possiblement, a través dels bucles homòlegs 1313-1332 i 778-787 (numeració dels residus), pertanyents, respectivament, als dominis de fosforilació de carbamato i bicarbonat. Per això, hem anomenat a ambd / Díez Fernández, C. (2015). USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/52855 / Compendio